Price:
Rs. 2,120.00
Sample Type: PULMONARY
Fasting Not Required
Frequently Asked Questions (FAQ's):
What is the AFB MDR Screen by Hain LPA, Pulmonary Test?
This test uses the Hain Line Probe Assay to detect Mycobacterium tuberculosis DNA and mutations linked to drug resistance against rifampicin and isoniazid in pulmonary samples.
Why is this test important?
It helps in the rapid detection of multidrug-resistant TB, enabling early modification of treatment regimens and preventing the spread of resistant strains.
Who should undergo this test?
Patients with suspected pulmonary TB, relapse cases, or those not responding to standard anti-TB therapy should undergo this test.
How is the test performed?
DNA is extracted from the pulmonary sample (such as sputum) and analyzed using the Hain Line Probe Assay at Metropolis Healthcare to identify resistance mutations.
What do the results indicate?
Results indicate whether the Mycobacterium tuberculosis strain is sensitive or resistant to rifampicin and isoniazid, helping guide effective treatment planning.
Are there any risks associated with the test?
The test is safe, with minimal procedural risk associated with sputum or pulmonary sample collection.
Why choose Metropolis Healthcare for this test?
Metropolis Healthcare offers rapid, accurate, and reliable molecular testing for MDR-TB using advanced Hain LPA technology and expert laboratory interpretation for optimal patient care.